Viking Therapeutics Shares Nosedive Toward Worst Day Ever
Digest more
Viking Therapeutics' stock recently tanked after reporting clinical trial results for an oral anti-obesity candidate. The healthcare company has an injectable version of its anti-obesity candidate in a phase 3 trial at the moment.
The oral formulation led to up to 12.2% weight loss over three months, a weaker outcome versus late-stage treatments from Eli Lilly and Novo Nordisk.
Viking's key drug demonstrated excellent body weight reduction data in a phase 2 trial, but its safety and tolerability data were disappointing.
We recently published 10 Stocks Hammered Harder Than Wall Street. Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of Tuesday’s worst performers. Viking Therapeutics fell by 42.12 percent on Tuesday to close at $24.
Viking Therapeutics Inc.’s worst stock drop in nine years has handed traders betting against the company a gain big enough to turn their money-losing year into a profitable one.
Viking Therapeutics ( VKTX -43.72%) stock collapsed on Tuesday, down 41.4% through 10:25 a.m. ET after reporting what pharmaceutical analysts are calling "mixed results" for its new GLP-1 weight loss pill, VK2735.
Viking Therapeutics (VKTX) stock drops as its oral obesity drug VK2735 trails Novo's (NVO) oral Wegovy and Lilly's (LLY) orforglipron in efficacy. Read more here.